{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:41:19Z","timestamp":1765806079320,"version":"3.41.2"},"reference-count":43,"publisher":"Becaris Publishing Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>To estimate the cost\u2013effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35\u00a0mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70\u00a0mg tablets (ALN) in Spain.<jats:bold>Methods:<\/jats:bold>A probabilistic analysis (second-order Monte Carlo simulation) was performed with a time horizon of 5\u00a0years, from the perspective of the Spanish National Health System. The bone fracture probabilities were obtained from a cohort study of 3614 women from USA with PMO treated with RIS-GR (1807) or ALN (1807) (Thomasius, 2022). The pharmacological cost and the cost of fractures were obtained from Spanish sources (\u20ac 2022). The utilities of patients with and without fracture (quality-adjusted life years [QALYs]) were obtained from the medical literature.<jats:bold>Results:<\/jats:bold>Compared with ALN, treatment with RIS-GR can avoid 79 fractures (between 75 and 82) every 1000 patients treated, and 0.0119 QALYs would be gained (between 0.0098 and 0.0140) per patient. Additionally, GR-RIS would generate a cost saving per patient of \u20ac1994 (\u20ac1437\u20132904) with a probability of 99.7%. The scenario analyses confirmed the stability of the base case results.<jats:bold>Conclusion:<\/jats:bold>According to this study, RIS-GR would be the dominant treatment (lower costs with QALY gain) compared with ALN.<\/jats:p>","DOI":"10.57264\/cer-2023-0115","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T12:42:08Z","timestamp":1694781728000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2013effectiveness of weekly gastro-resistant risedronate 35\u00a0mg, compared with weekly alendronate 70\u00a0mg tablets, in the treatment of postmenopausal osteoporosis in Spain"],"prefix":"10.57264","volume":"12","author":[{"given":"Enrique","family":"Casado","sequence":"first","affiliation":[{"name":"Rheumatology Department, Parc Taul\u00ed Hospital Universitari. Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Rosas","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hosp. Marina Baixa de la Vila Joiosa, Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rubio-Terr\u00e9s","sequence":"additional","affiliation":[{"name":"Health Value, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo","family":"Rubio-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Health Value, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitra","family":"Boolell","sequence":"additional","affiliation":[{"name":"Medical Affairs, 50 Broadway, London, SW1H OBL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Ar\u00edstegui","sequence":"additional","affiliation":[{"name":"Medical Affairs, 50 Broadway, London, SW1H OBL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785\u2013795 (2001).","journal-title":"JAMA"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/joim.12369","article-title":"Osteoporosis: the evolution of a diagnosis","volume":"277","author":"Lorentzon M","year":"2015","unstructured":"Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J. Intern. Med. 277, 650\u2013661 (2015).","journal-title":"J. Intern. Med."},{"key":"e_1_3_5_5_2","unstructured":"Osteoporosis: new online map shows burden across Europe (2023). https:\/\/healthcare-in-europe.com\/en\/news\/osteoporosis-map-burden-europe"},{"key":"e_1_3_5_6_2","unstructured":"SCOPE 2021 Report (2023). https:\/\/www.osteoporosis.foundation\/scope-2021"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021: a new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis JA","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch. Osteoporos. 16, 82 (2021).","journal-title":"Arch. Osteoporos."},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1759720X2210835","DOI":"10.1177\/1759720X221083541","article-title":"Osteoporosis in 10 years' time: a glimpse into the future of osteoporosis","volume":"14","author":"Adami G","year":"2022","unstructured":"Adami G, Fassio A, Gatti D Osteoporosis in 10 years' time: a glimpse into the future of osteoporosis. Ther. Adv. Musculoskelet. Dis. 14, 1759720X221083541 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis JA","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 30, 3\u201344 (2019).","journal-title":"Osteoporos. Int."},{"key":"e_1_3_5_10_2","first-page":"488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation","volume":"4","author":"Ettinger B","year":"1998","unstructured":"Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J. Manag. Care Pharm. 4, 488\u2013492 (1998).","journal-title":"J. Manag. Care Pharm."},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3109\/13697137.2014.995164","article-title":"Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter","volume":"18","author":"Vytrisalova M","year":"2015","unstructured":"Vytrisalova M, Touskova T, Ladova K Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. Climacteric 18, 608\u2013616 (2015).","journal-title":"Climacteric"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/14737167.2016.1171145","article-title":"Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost","volume":"16","author":"Chodick G","year":"2016","unstructured":"Chodick G, Moser SS, Goldshtein I. Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. Expert Rev. Pharmacoecon. Outcomes Res. 16, 359\u2013370 (2016).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/TCRM.S52291","article-title":"Eliminating the need for fasting with oral administration of bisphosphonates","volume":"9","author":"Pazianas M","year":"2013","unstructured":"Pazianas M, Abrahamsen B, Ferrari S, Russell RG. Eliminating the need for fasting with oral administration of bisphosphonates. Ther. Clin. Risk Manag. 9, 395\u2013402 (2013).","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00198-012-2175-7","article-title":"Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years","volume":"24","author":"McClung MR","year":"2013","unstructured":"McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos. Int. 24, 301\u2013310 (2013).","journal-title":"Osteoporos. Int."},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00198-021-06108-w","article-title":"Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis","volume":"33","author":"Thomasius F","year":"2022","unstructured":"Thomasius F, Palacios S, Alam A, Boolell M, Vekeman F, Gauthier G. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. Osteoporos. Int. 33, 217\u2013228 (2022).","journal-title":"Osteoporos. Int."},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00198-018-04821-7","article-title":"Cost effectiveness of gastro resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France","volume":"30","author":"Hiligsmann M","year":"2019","unstructured":"Hiligsmann M, Reginster JY. Cost effectiveness of gastro resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporos. Int. 30, 649\u2013658 (2019).","journal-title":"Osteoporos. Int."},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs A","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press, UK (2006)."},{"key":"e_1_3_5_18_2","first-page":"1000e102","article-title":"Probabilistic analysis: sensitivity analysis or main result? [editorial]","volume":"1","author":"Rubio-Terr\u00e9s C","year":"2016","unstructured":"Rubio-Terr\u00e9s C, Rubio-Rodr\u00edguez D. Probabilistic analysis: sensitivity analysis or main result? [editorial]. Pharmacoecon. Open 1, 1000e102 (2016).","journal-title":"Pharmacoecon. Open"},{"issue":"2","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14737167.2020.1789457","article-title":"Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain","volume":"21","author":"Kim HK","year":"2021","unstructured":"Kim HK, Peral C, Rubio-Rodr\u00edguez D, Rubio-Terr\u00e9s C. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain. Expert Rev. Pharmacoecon. Outcomes Res. 21(2), 315\u2013320 (2021).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14737167.2021.1933948","article-title":"Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain","volume":"21","author":"Formiga F","year":"2021","unstructured":"Formiga F, Garc\u00eda-Pav\u00eda P, Mart\u00edn S\u00e1nchez FJ Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. Expert Rev. Pharmacoecon. Outcomes Res. 21, 1127\u20131133 (2021).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_5_21_2","first-page":"56","article-title":"Cost of osteoporotic hip fracture in Spain per Autonomous Region","volume":"63","author":"Bartra A","year":"2019","unstructured":"Bartra A, Caeiro JR, Mesa-Ramos M en representaci\u00f3n de los investigadores del estudio PROA. Cost of osteoporotic hip fracture in Spain per Autonomous Region. Rev. Esp. Cir. Ortop. Traumatol. (Engl. Ed.) 63, 56\u201368 (2019).","journal-title":"Rev. Esp. Cir. Ortop. Traumatol. (Engl. Ed.)"},{"key":"e_1_3_5_22_2","unstructured":"BotPlus (2022). https:\/\/botplusweb.portalfarma.com"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CEOR.S78349","article-title":"Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain","volume":"7","author":"Darb\u00e1 J","year":"2015","unstructured":"Darb\u00e1 J, Kaskens L, Sorio Vilela F, Lothgren M. Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clinicoecon. Outcomes Res. 7, 105\u2013117 (2015).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"e_1_3_5_24_2","unstructured":"INE. Tablas de mortalidad por a\u00f1o sexo edad y funciones. Resultados nacionales por comunidades aut\u00f3nomas y provincias. Instituto Nacional de Estad\u00edstica (2022). https:\/\/ine.es"},{"key":"e_1_3_5_25_2","unstructured":"Ley 20\/2017 de 28 de diciembre de tasas. BOE N\u00b0 38 12 de febrero de 2018: 16727 (2023). https:\/\/www.boe.es\/eli\/es-vc\/l\/2017\/12\/28\/20\/dof\/spa\/pdf"},{"key":"e_1_3_5_26_2","unstructured":"Orden 727\/2017 de 7 de agosto del consejero de Sanidad por la que se fijan los precios p\u00fablicos por la prestaci\u00f3n de los servicios y actividades de naturaleza sanitaria de la red de centros de la Comunidad de Madrid. BOCM N\u00b0 198 21 de agosto de 2017 (2023). http:\/\/www.madrid.org\/wleg_pub\/#"},{"key":"e_1_3_5_27_2","unstructured":"Orden SAN\/35\/2017 de 15 de diciembre por la que se fijan las cuant\u00edas de los Precios P\u00fablicos de los Servicios Sanitarios prestados por el Servicio C\u00e1ntabro de Salud. BOC N\u00b0 248 29 de diciembre de 2017 (2023). https:\/\/boc.cantabria.es\/boces\/verAnuncioAction.do?idAnuBlob=320839"},{"key":"e_1_3_5_28_2","unstructured":"Orden SLT\/71\/2020 de 2 de junio por la que se regulan los supuestos y conceptos facturables y se aprueban los precios p\u00fablicos correspondientes a los servicios que presta el Instituto Catal\u00e1n de la Salud. DOGC N\u00b0 8153 12 de junio de 2020 (2023). https:\/\/vlex.es\/vid\/orden-slt-71-2020-845025418"},{"key":"e_1_3_5_29_2","unstructured":"Precios p\u00fablicos de servicios sanitarios prestados en el SSPA. 28\/10\/2021 (2022). https:\/\/datos.gob.es\/es\/catalogo\/a01002820-precios-publicos-de-servicios-sanitarios-prestados-en-el-sspa"},{"key":"e_1_3_5_30_2","unstructured":"Resoluci\u00f3n del director general del Servicio de Salud de las Islas Baleares por la que se modifica la Orden de la consejera de Salud y Consumo de 22 de diciembre de 2006 por la que se establecen los precios p\u00fablicos a aplicar por los centros sanitarios de la Red P\u00fablica de las Islas Baleares por la prestaci\u00f3n de servicios sanitarios cuando existan terceros obligados al pago o usuarios sin derecho a asistencia sanitaria de la Seguridad Social. BOIB N\u00b0 2 4 de enero de 2018: 111 (2023). http:\/\/www.caib.es\/eboibfront\/pdf\/es\/2018\/2\/998038"},{"key":"e_1_3_5_31_2","unstructured":"Resoluci\u00f3n 1564\/2018 de 20 de diciembre del Director Gerente del Servicio Navarro de Salud por la que se fijan las tarifas por los servicios prestados por el Servicio Navarro de Salud. BON N\u00b0 14 22 de enero de 2019 (2023). https:\/\/bon.navarra.es\/es\/anuncio\/-\/texto\/2019\/14\/5"},{"key":"e_1_3_5_32_2","unstructured":"Resoluci\u00f3n SLT\/474\/2022 de 25 de febrero sobre la revisi\u00f3n de precios p\u00fablicos correspondientes a los servicios sanitarios que presta el Instituto Catal\u00e1n de la Salud. DOGC N\u00b0 8617 2 de marzo de 2022 (2023). https:\/\/noticias.juridicas.com\/base_datos\/CCAA\/720757-r-slt-474-2022-de-25-feb-ca-cataluna-revision-de-precios-publicos-correspondientes.html"},{"key":"e_1_3_5_33_2","unstructured":"Tarifas para facturaci\u00f3n de servicios sanitarios y docentes del Servicio vasco de salud para el a\u00f1o 2021. Vitoria: departamento vasco de salud diciembre de 2020 (2023). https:\/\/www.osakidetza.euskadi.eus\/contenidos\/informacion\/osk_servic_para_empresas\/es_def\/adjuntos\/Libro_de_Tarifas_2022_CAS.pdf"},{"key":"e_1_3_5_34_2","unstructured":"Reflection paper on the extrapolation of results from clinical studies conducted outside the USA to the EU-population. Committee for Medicinal Products for Human Use (CHMP): EMEA\/CHMP\/EWP\/692702\/2008. London (2023). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-extrapolation-results-clinical-studies-conducted-outside-european-union-eu-eu_en.pdf"},{"key":"e_1_3_5_35_2","unstructured":"Note for guidance on ethnic factors in the acceptability of foreign clinical data (CPMP\/ICH\/289\/95). CHMP\/ICH\/289\/95. 1998 Sep (2023). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-5-r1-ethnic-factors-acceptability-foreign-clinical-data-step-5_en.pdf"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2474","article-title":"The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications","volume":"111","author":"Purpura CA","year":"2022","unstructured":"Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Clin. Pharmacol. Ther. 111, 135\u2013144 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_5_37_2","unstructured":"Atlas de Variaciones en la Pr\u00e1ctica M\u00e9dica (2022). https:\/\/www.atlasvpm.org\/"},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"e0253450","DOI":"10.1371\/journal.pone.0253450","article-title":"Health care system efficiency and life expectancy: a 140-country study","volume":"16","author":"Zarulli V","year":"2021","unstructured":"Zarulli V, Sopina E, Toffolutti V, Lenart A. Health care system efficiency and life expectancy: a 140-country study. PLOS ONE 16, e0253450 (2021).","journal-title":"PLOS ONE"},{"key":"e_1_3_5_39_2","unstructured":"Esperanza de vida al nacer. 2020. Mujeres y hombres (2023). https:\/\/www.ine.es\/jaxi\/Tabla.htm?path=\/t00\/mujeres_hombres\/tablas_2\/&file=d2g4.px"},{"key":"e_1_3_5_40_2","unstructured":"La esperanza de vida retrocede en Estados Unidos hasta los 77 28 a\u00f1os (2023). https:\/\/datosmacro.expansion.com\/demografia\/esperanza-vida\/usa"},{"key":"e_1_3_5_41_2","unstructured":"Rubio-Terr\u00e9s C Rubio-Rodr\u00edguez D. Glosario de Farmacoeconom\u00eda. 30 de septiembre de 2019 (2022). https:\/\/www.healthvalue.org\/pdfs\/ GLOSARIO%20DE%20FARMACOECONOM%-C3%8DA.pdf"},{"key":"e_1_3_5_42_2","first-page":"97","article-title":"An\u00e1lisis farmacoecon\u00f3mico del tratamiento de la osteoporosis postmenop\u00e1usica con risedronato o alendronato","volume":"11","author":"Hart WM","year":"2002","unstructured":"Hart WM, Rubio-Terr\u00e9s C, Burrell A, Ar\u00edstegui I, Escobar-Jim\u00e9nez F. An\u00e1lisis farmacoecon\u00f3mico del tratamiento de la osteoporosis postmenop\u00e1usica con risedronato o alendronato. REEMO 11, 97\u2013104 (2002).","journal-title":"REEMO"},{"key":"e_1_3_5_43_2","first-page":"9","article-title":"An\u00e1lisis farmacoecon\u00f3mico de risedronato semanal frente a alendronato semanal en Espa\u00f1a","volume":"18","author":"Beteg\u00f3n L","year":"2009","unstructured":"Beteg\u00f3n L, G\u00f3mez C, Marqu\u00e9s M. An\u00e1lisis farmacoecon\u00f3mico de risedronato semanal frente a alendronato semanal en Espa\u00f1a. REEMO 18, 9\u201314 (2009).","journal-title":"REEMO"},{"key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2474-8-97","article-title":"The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review","volume":"8","author":"Adachi J","year":"2007","unstructured":"Adachi J, Lynch N, Middelhoven H The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet. Disord. 8, 97 (2007).","journal-title":"BMC Musculoskelet. Disord."},{"key":"e_1_3_5_45_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bonr.2015.10.006","article-title":"Association between gastrointestinal events and compliance with osteoporosis therapy","volume":"4","author":"Siris ES","year":"2016","unstructured":"Siris ES, Fan CPS, Yang X Association between gastrointestinal events and compliance with osteoporosis therapy. Bone Rep. 4, 5\u201310 (2016).","journal-title":"Bone Rep."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T21:33:53Z","timestamp":1703194433000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.57264\/cer-2023-0115"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0115","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2023,11]]},"article-number":"e230115"}}